The role of high-dose chemotherapy in the treatment of non-small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 2, 2002, Pages 151-156

  Fetscher, Sebastian ^a  

^a City Hospital South   (Germany)

Author keywords

Hematopoietic growth factors; High dose chemotherapy; Non small cell lung cancer; Peripheral blood stem cell transplantation; Standard dose chemotherapy; Treatment related mortality

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG MEGADOSE; DRUG TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; MORBIDITY; MORTALITY; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; THORAX;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GROWTH SUBSTANCES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036171685     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00152-4     Document Type: Review

References (62)

1. Chemotherapy of lung cancer
2. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalagamation algorithms in 1052 patients
3. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis
4. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIA non-small cell lung cancer: an Intergroup trial (E3590)
5. Adjuvant chemotherapy after radical surgery for non small cell lung cancer: a randomized study
6. Adjuvant chemotherapy after complete resection in non-small cell lung cancer. Western Japan Study Group for Lung Cancer Surgery
7. Concurrent cisplatin-etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB (N3) non-small cell lung cancer: mature results of SWOG 8805
8. Concurrent cisplatin/etoposide plus radiotherapy for pathologic stage IIIB non-small cell lung cancer: a SWOG phase II study
9. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer
10. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial
11. Hyperfraction-nated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study
12. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC)
13. Neoadjuvant chemotherapy increases perioperative complications in patients undergoing resection for NSCLC
14. A randomized trial comparing pre-operative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer
15. A randomized trial comparing pre-operative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer
16. Radiosensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group
17. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol
18. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small cell lung cancer
19. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer
20. New chemotherapeutic agents prolong survival and improve qualitiy of life in non-small cell lung cancer: a review of the literature and future directions
21. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Trial
22. Activity of doxcetacel in platinum-treated non-small cell lung cancer: results of a phase II multicenter trial
23. Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small cell lung cancer
24. Induction chemotherapy with and without human granulocyte colony-stimulation factor in locally advanced IIIA/IIIB non-small cell lung cancer
25. Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer
26. Dose-intensive ifosfamide/carbo-platin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer
27. The role of granulocyte growth factors in the treatment of non-small cell lung cancer
28. Routine use of colony-stimulating factors is not cost effective and dose not increase patient comfort in the treatment of small cell lung cancer: an analysis using a Markov model
29. Enhancing myelotoxicity due to granulocyte colony-stimulating factor until 48 hours before next chemotherapy course in patients in patients with small cell lung carcinoma
30. High-dose chemotherapy with autologous bone marrow/stem-cell rescue in lung cancer
31. Dose-intense therapy with Etoposide, Ifosfamide, Cisplatin, and Epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small cell lung cancer
32. Dose-intense therapy with Etoposide, Ifosfamide, Cisplatin, and Epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small cell lung cancer a mature follow-up report
33. Late intensification chemotherapy with autologous bone marrow transplantation for small cell carcinoma of the lung
34. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer
35. Autologous bone marrow transplantation for the treatment of lung cancer
36. Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer
37. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung
38. High-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and peripheral blood stem-cell support in non-small-cell lung cancer
39. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in treatment of small cell lung carcinoma
40. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer
41. Intensive chemotherapy with autologous bone marrow transplantation for small cell lung cancer
42. High-dose multiple-alkylator chemotherapy with autologous bone marrow infusion in patients with advanced non-small-cell lung cancer
43. High dose combination chemotherapy with ifosfamide, cyclophosphamide, cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell carcinoma of the lung
44. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer
45. Gemcitabine in the treatment of non-small-cell lung cancer
46. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced metastatic non-small cell lung cancer
47. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study
48. A randomized trial of gemcitabine-cisplatin (GC) versus mitomycine, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC). A multicenter phase III study
49. Single-agent gemcitabine versus cisplatin plus etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer
50. Significantly higher survival with gemcitabine-cisplatin versus cisplatin in advanced non-small cell lung cancer (NSCLC): Final results from an international randomized phase III study
51. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)
52. Comparison of survival for stage IIIB versus stage IV non-small cell lung cancer (NSCLC) patients treated with etoposide-cisplatin versus Taxol®-cisplatin: An Eastern Cooperative Group (ECOG) trial
53. Docetaxel is active in non-small cell lung cancer: A phase II trial of the EORTC early clinical trials group (LCTG)
54. Paclitaxel plus Carboplatin: an effective combination chemotherapy for advanced non-small-cell lung cancer or just another Elvis sighting
55. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer
56. Phase II trial of a 3-hour infusion of Paclitaxel in previously untreated patients with advanced non-small-cell lung cancer
57. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer